» Articles » PMID: 38153641

Sufficient Regional Lymph Node Examination for Staging Adenocarcinoma of the Appendix

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2023 Dec 28
PMID 38153641
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The presence of lymph node (LN) metastasis is a known negative prognostic factor in appendix cancer (AC) patients. However, currently the minimum number of LNs required to adequately determine LN negativity is extrapolated from colorectal studies and data specific to AC is lacking. We aimed to define the lowest number of LNs required to adequately stage AC and assess its impact on oncologic outcomes.

Methods: Patients with stage II-III AC from the National Cancer Database (NCDB 2004-2019) undergoing surgical resection with complete information about LN examination were included. Multivariable logistic regression assessed the odds of LN positive (LNP) disease for different numbers of LNs examined. Multivariable Cox regressions were performed by LN status subgroups, adjusted by prognostic factors, including grade, histologic subtype, surgical approach, and documented adjuvant systemic chemotherapy.

Results: Overall, 3,602 patients were included, from which 1,026 (28.5%) were LNP. Harvesting ten LNs was the minimum number required without decreased odds of LNP compared with the reference category (≥ 20 LNs). Total LNs examined were < 10 in 466 (12.9%) patients. Median follow-up from diagnosis was 75.4 months. Failing to evaluate at least ten LNs was an independent negative prognostic factor for overall survival (adjusted hazard ratio 1.39, p < 0.01).

Conclusions: In appendix adenocarcinoma, examining a minimum of ten LNs was necessary to minimize the risk of missing LNP disease and was associated with improved overall survival rates. To mitigate the risk of misclassification, an adequate number of regional LNs must be assessed to determine LN status.

Citing Articles

ASO Author Reflections: Leave No Stone Unturned-Confidently Ruling Out Metastatic Lymph Node Disease in Appendix Cancer.

Lopez-Ramirez F, King M, Sardi A, Gushchin V Ann Surg Oncol. 2023; 31(3):1783-1784.

PMID: 38071701 DOI: 10.1245/s10434-023-14773-w.

References
1.
van den Heuvel M, Lemmens V, Verhoeven R, de Hingh I . The incidence of mucinous appendiceal malignancies: a population-based study. Int J Colorectal Dis. 2013; 28(9):1307-10. DOI: 10.1007/s00384-013-1714-9. View

2.
Orchard P, Preece R, Thomas M, Dixon S, Wong N, Chambers A . Demographic trends in the incidence of malignant appendiceal tumours in England between 1995 and 2016: Population-based analysis. BJS Open. 2022; 6(4). PMC: 9418812. DOI: 10.1093/bjsopen/zrac103. View

3.
Singh H, Koomson A, Decker K, Park J, Demers A . Continued increasing incidence of malignant appendiceal tumors in Canada and the United States: A population-based study. Cancer. 2020; 126(10):2206-2216. DOI: 10.1002/cncr.32793. View

4.
Chen G, Chen K, Sahyoun L, Zaman S, Protiva P . Appendiceal adenocarcinoma is associated with better prognosis than cecal adenocarcinoma: a population-based comparative survival study. BMJ Open Gastroenterol. 2023; 10(1). PMC: 9950880. DOI: 10.1136/bmjgast-2022-001045. View

5.
Tokunaga R, Xiu J, Johnston C, Goldberg R, Philip P, Seeber A . Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. Clin Cancer Res. 2019; 25(10):3096-3103. PMC: 6886223. DOI: 10.1158/1078-0432.CCR-18-3388. View